316 CHAPTER 4.1 Table SI1.2. Continued START criteria (n=31) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) E 2. Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid therapy. 69 52.2% 12 75.0% 25 48.0% 10 80.0% 22 31.8% A 3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, cerebral or peripheral vascular disease. 59 37.3% 4 50.0% 35 22.9% 8 50.0% 12 66.7% A 8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failure. 58 22.4% 4 25.0% 24 25.0% 6 83.3% 24 4.2% G 1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary. 53 24.5% 4 25.0% 35 31.4% 1 0% 13 7.7% B 3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or SaO2 < 89%) 52 0% 1 0% 42 0% 7 0% 2 0.0% A 4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/ or diastolic blood pressure consistently >90 mmHg; if systolic blood pressure > 140 mmHg and /or diastolic blood pressure > 90 mmHg, if diabetic. 49 24.5% 11 36.4% 10 20.0% 5 60.0% 23 13.0%
RkJQdWJsaXNoZXIy MTk4NDMw